Edgewise Therapeutics, Inc., a Delaware corporation incorporated in May 2017, is headquartered in Boulder, Colorado. The company is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing new therapies for serious, rare muscle diseases with unmet medical needs. The Company's lead product candidate, EDG-5506, is an oral small molecule drug designed to address the underlying causes of malnutrition, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). A pipeline of precision drug candidates for major muscle proteins and regulators to address a broad range of genetically defined muscle diseases. 

Expected P&L on Expiry

Key Stats

Pricing Model

About EWTX20260220P25